Product Liability “FDA Defense” Prospects Hampered By Vioxx Shrapnel
This article was originally published in The Tan Sheet
Executive Summary
An "FDA defense" from product liability punitive damages will be a tough sell on Capitol Hill in the next session, in light of burgeoning concerns about FDA's handling of Vioxx and agency oversight of approvals and postmarketing
You may also be interested in...
Federal Pre-emption Defense Under Fire In Draft House Bills
A one-sentence provision tucked into draft House legislation renewing FDA's drug user fee program seeks to weaken manufacturers' ability to use FDA approval as a defense in state product liability lawsuits
Vioxx Hearing Witnesses Push For Independent Drug Safety Office
The proposal to create an independent Office of Drug Safety at FDA may be gaining momentum, following a congressional hearing reviewing FDA's handling of Merck's Vioxx (rofecoxib)
Malpractice Punitive Damage Cap Bills To Return; CHPA Goes To Washington
Provisions protecting manufacturers of FDA-approved products from punitive damages are likely to continue appearing in medical malpractice award limit bills this session